Prognostic significance of the biological subtype for the choice of surgical treatment tactics for early breast cancer (Literature review)
Abstract
The purpose of this systematic review is to identify the dependence of the subtype of breast cancer and the risk of developing a local-regional recurrence after breast-conserving surgery and radical mastectomy. The main predictors in the development of relapse in breast cancer can be considered young age, the degree of tumor malignancy, the size of the tumor node, the presence of lymphovascular invasion or lymph node involvement and adverse tumor subtypes. At present, there is no single-valued data on the choice of surgical treatment tactics for various biological subtypes, however effective systemic therapy as well as radiotherapy reduces the frequency of local recurrences after performing breast-conserving surgery in unfavorable tumor subtypes and, according to the results of studies, the overall and disease-free survival is comparable, as in the case of mastectomy. Breast-conserving surgery can be performed in young patients with unfavorable tumor subtypes, provided all the possibilities of modern chemoradiotherapy are used.
About the Authors
O. Ju. Gorbacheva
FGBU «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia
Russian Federation
Russian Federation
V. Ju. Ivashkov
FGBU «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia
Russian Federation
Russian Federation
V. A. Sobolevsky
FGBU «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia
Russian Federation
Russian Federation
O. V. Krohina
FGBU «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Давыдов МИ, Аксель ЕМ. Статистика злокачественных новообразований в России и странах СНГ в 2013 году. Вестник РОНЦ им. Н.Н. Блохина РАМН, 2015.
2. Переводчикова НИ, Стенина МБ. Лекарственная терапия рака молочной железы. М.: Практика, 2014.
3. Стенина МБ, Жукова ЛГ, Королева ИА, Пароконная АА и соавт. Практические рекомендации по лекарственному лечению злокачественных опухолей. Инвазивный рак молочной железы. М., Злокачественные опухоли. 2017;7(3):114-115.
4. Семиглазов ВФ, Палтуев РМ, Семиглазов ВВ, Манихас АГ и соавт. Ранний рак молочной железы: прогностическое значение биологических подтипов (анализ кумулятивной базы данных ФГБУ НИИ онкологии им. Н.Н. Петрова» Минздравсоцразвития. Злокачественные опухоли. 2012;2(2):12-18.
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2014. International Journal of Cancer. 2014;136(5):E359-E386.
6. Gucalp A, Gupta G, Pilewskie M, Sutton E, Norton L. Advances in managing breast cancer: a clinical update. 2014/ F1000Prime Reports, 6.
7. Beaber E, Buist D, Barlow W, Malone K. Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age. Cancer Research. 2014;74(15):4078-4089.
8. Kennecke H, Yerushalmi R, Woods R, Cheang M, Voduc D, Speers C, Nielsen T, Gelmon K. Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology. 2010;28(20):3271-3277.
9. Senn H. St. Gallen Consensus 2013: Optimizing and Personalizing Primary Curative Therapy of Breast Cancer Worldwide. Breast Care. 2013;8(2):101-101.
10. Arvold N, Taghian A, Niemierko A, Abi Raad R. Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology. 2011;29(29):3885-3891.
11. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, Bahoric B, Sultanem K, Muanza T Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Cureus. 2016.
12. Tran B, Bedard P. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Research. 2011;13(6).
13. Chen S, Huang L, Chen C, Shao Z. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. Oncotarget. 2015;6(20).
14. Prat A, Cheang M, Martin M, Parker J. Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. Journal of Clinical Oncology. 2011;31(2):203-209.
15. Laurberg T, Alsner J, Tramm T, Jensen V, Lyngholm C. Impact of age, intrinsic subtype and local treatment on longterm local-regional recurrence and breast cancer mortality among low-risk breast cancer patients. Acta Oncologica. 2016;56(1):59-67.
16. Viale G, Regan M, Maiorano E, Mastropasqua MA. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98. Journal of Clinical Oncology. 2007;25(25):3846-3852.
17. Engel J, Eckel R, Aydemir Ü. Determinants and prognoses of locoregional and distant progression in breast cancer. International Journal of Radiation. International Journal of Radiation Oncology Biology Physics. 2003;55(5):1186-1195.
18. Albert J, Buchholz T. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Breast Diseases: A Year Book Quarterly. 2012;23(3):288-289.
19. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
20. Liedtke C, Mazouni C, Hess K, André F. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. 2008;26(8):1275-1281.
21. Gangi A, Chung A, Mirocha J, Liou D. Breast-Conserving Therapy for Triple-Negative Breast Cancer. JAMA Surgery. 2014;149(3):252.
22. Abdulkarim B, Cuartero J, Hanson J, Deschênes J. Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy. Journal of Clinical Oncology. 2011;29(21):2852-2858.
23. Adkins F, Gonzalez-Angulo A, Lei X, Hernandez-Aya L. Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Annals of Surgical Oncology. 2011;18(11):3164-3173.
24. Zumsteg Z, Morrow M, Arnold B, Zheng J. Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer. Annals of Surgical Oncology. 2013;20(11):3469-3476.
25. Yang T Morrow M, Modi S, Zhang Z. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. Annals of Surgical Oncology. 2015;22(S3):495-501.
26. Wong F, Chua E. Hormone Receptors and HER-2 Status as Surrogates for Histological Subtypes Prognosticate for Disease Control in Node Negative Asian Breast Cancer Patients Treated with Breast Conservation Therapy. International Journal of Radiation Oncology Biology Physics. 2011;75(3):S183-S184.
27. Siponen E, Joensuu H, Vironen J, Heikkilä P. Ipsilateral breast recurrence after breast conserving surgery in patients with small (≤2 cm) breast cancer treated with modern adjuvant therapies Vaalavirta. European Journal of Surgical Oncology (EJSO). 2011;37(1):25-31.
28. Abdulkaraim H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, Moo T The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy. The Breast Journal. 2017:S183-S184.
29. Braunstein L, Taghian A, Niemierko A, Salama L. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Research and Treatment. 2016;161(1):173-179.
30. Mannino М, Yarnold J. Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld? Radiotherapy and Oncology. 2009;90(1):14-22.
31. Nguyen P, Taghian A, Katz M et al. Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology. 2009;26(14):2373-2378.
32. Lowery A, Kell M, Glynn R, Kerin M, Sweeney K. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment. Breast Cancer Research and Treatment. 2011;133(3):831-841.
33. Wang J, Xie X, Wang X, Tang J. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis. Surgical Oncology. 2013;22(4):247-255.
34. Moran M. Radiation therapy in the locoregional treatment of triple-negative breast cancer. The Lancet Oncology. 2015;16(3):e113-e122.
35. King T, Radosa J, Eaton A, Stempel M, Khander A. Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. Annals of Surgical Oncology. 2016;24(3):698-704.
36. Gnant M., Harbeck N et al. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care. 2017;12(2):102-107.
37. Chen Q., Wang X, Lin P, Zhang J. The different outcomes between breast-conserving surgery and mastectomy in tri ple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget. 2016;8(3).
38. Alabdulkareem H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, Moo T The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy. The Breast Journal. 2017:S183-S184.
Review
For citations:
Gorbacheva O.J., Ivashkov V.J., Sobolevsky V.A., Krohina O.V. Prognostic significance of the biological subtype for the choice of surgical treatment tactics for early breast cancer (Literature review). Bone and soft tissue sarcomas, tumors of the skin. 2018;10(2):60-65. (In Russ.)
Views:
89
Email this article 
